Rufinamide

Rufinamide is a board spectrum anticonvulsant. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide was approved by the US Food and Drug Administration on November 14, 2008 as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults. Rufinamide has efficacy for partial seizures. Rufinamide prolongs the inactivation of sodium channels and limits the frequency of action potential firing in cultured and acutely isolated neurons.

Properties:
Appearance & Physical State: white powder
Density: 1.52 g/cm3
Boiling Point: 473.8ºC at 760 mmHg
Flash Point: 240.4ºC
Refractive Index: 1.634
Vapor Pressure: 3.81E-09mmHg at 25°C

Sodium Channel Inhibitors Related Products:  

Carbamazepine; A-803467; Camostat Mesilate; Ambroxol hcl; Proparacaine hydrochloride; Zonisamide; Zonisamide sodium salt; Dronedarone hcl; Baricitinib; Levobupivacaine; Levobupivacaine hcl; Vinpocetine; Propafenone hcl; Lamotrigine

[1]. Suter MR, Kirschmann G, Laedermann CJ, Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118(1):160-72.

[2]. White HS, Franklin MR, Kupferberg HJ, The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49(7):1213-20.